Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Hematologic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 9Nivolumab 4Magnetic Resonance Spectroscopy 3spartalizumab 2Ipilimumab 2Gemcitabine 2Fluorodeoxyglucose F18 2FAPI-46 2Drug Therapy 2Cisplatin 2zenocutuzumab 1venetoclax 1ulixertinib 1trametinib 1tislelizumab 1seribantumab 1rovalpituzumab tesirine 1pazopanib 1neratinib 1margetuximab 1lenvatinib 1entrectinib 1durvalumab 1cobimetinib 1cemiplimab 1budigalimab 1bemarituzumab 1atezolizumab 1alectinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × margetuximab × Head & Neck × Clear all
NCT03219268 2023-12-21

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

MacroGenics

Phase 1 Completed
277 enrolled
BreastGastrointestinalGynecologicHead & NeckOther hematologic neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Hematologic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡